Germ-line mutations in the *BRCA1* and *BRCA2* genes confer a high lifetime risk of developing breast and other cancers. Estimates of the cumulative risk of breast cancer to age 70 years vary from 40% to 85% ([Easton *et al*, 1995](#bib6){ref-type="other"}; [Ford *et al*, 1998](#bib8){ref-type="other"}; [Antoniou *et al*, 2003](#bib1){ref-type="other"}; [Chen *et al*, 2006](#bib4){ref-type="other"}; [Milne *et al*, 2008](#bib15){ref-type="other"}). Other genetic and/or environmental factors (modifiers) are likely to explain these differences, at least in part. Because of the large sample size required to identify such effects, few reliable associations have been reported to date, all coming from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) initiative, which was set up to provide large samples of *BRCA1* and *BRCA2* mutation carriers to reliably assess even modest associations with single nucleotide polymorphisms (SNPs) ([Chenevix-Trench *et al*, 2007](#bib5){ref-type="other"}). Recently, CIMBA assessed three SNPs in the *FGFR2*, *TNRC9* and *MAP3K1* genes that had been previously found by a genome-wide association study to be associated with increased breast cancer risk for women in the general population ([Easton *et al*, 2007](#bib7){ref-type="other"}). Consistent associations were found for *BRCA1* and/or *BRCA2* mutation carriers ([Antoniou *et al*, 2008](#bib3){ref-type="other"}), indicating that SNPs involved in the susceptibility to develop breast cancer in the general population are good candidates to be tested as potential modifiers in *BRCA1* and *BRCA2* mutation carriers.

The *ERCC4* gene is involved in the nucleotide excision repair (NER) pathway, which has led to the investigation of its role in the susceptibility to develop different types of cancer including breast cancer ([Garcia-Closas *et al*, 2006](#bib9){ref-type="other"}; [Mechanic *et al*, 2006](#bib14){ref-type="other"}; [Moreno *et al*, 2006](#bib17){ref-type="other"}; [Kiyohara and Yoshimasu, 2007](#bib12){ref-type="other"}; [Hooker *et al*, 2008](#bib11){ref-type="other"}; [Smith *et al*, 2008](#bib19){ref-type="other"}). We previously reported that the minor G allele in a SNP on intron 1 of *ERCC4* (rs744154) was associated with protection from breast cancer in the general population (OR under a recessive model 0.61; *P*=0.0002) ([Milne *et al*, 2006](#bib16){ref-type="other"}). On the basis of this finding, we aimed to assess *ERCC4*-rs744154 as a breast cancer risk modifier in *BRCA1* and *BRCA2* mutation carriers. The study was performed in two stages, the first comprising 837 mutation carriers from three CIMBA centres, and the second comprising 15 040 mutation carriers from all the CIMBA studies, including those used in stage I.

Materials and methods
=====================

Subjects
--------

Eligible subjects were female carriers of deleterious mutations in *BRCA1* and *BRCA2* aged 18 years or older. Further details regarding eligibility and the information collected from subjects are described elsewhere ([Antoniou *et al*, 2008](#bib3){ref-type="other"}). Subjects who reported having ethnicity other than White European were excluded. This gave a total of 15 040 female mutation carriers (9408 with mutations in *BRCA1* and 5632 with mutations in *BRCA2*), 8088 of whom had been diagnosed with breast cancer (4956 and 3132 with mutations in *BRCA1* and *BRCA2*, respectively). All carriers participated in clinical or research studies at the host institution under ethically approved protocols.

A total of 34 collaborating CIMBA studies, carried out in 18 countries, contributed genotype data for *ERCC4*-rs744154 to this study. Details of each study along with the number of samples included from each are provided in [Table 1](#tbl1){ref-type="table"}. Seven studies (CBCS, GOG, ILUH, MSKCC, NNPIO, OSUCCG and IOVHBOCS) had not participated in previous CIMBA collaborations ([Antoniou *et al*, 2008](#bib3){ref-type="other"}). Subjects from the CNIO, HEBCS and MBCSG studies were used in the first stage and comprised 837 mutation carriers (469 in *BRCA1* and 368 in *BRCA2*). All 9408 *BRCA1* and 5632 *BRCA2* mutation carriers CIMBA subjects were included in the second stage.

Genotyping
----------

The genotyping platform used by each study is detailed in [Table 1](#tbl1){ref-type="table"}. For 11 studies, matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF MS) was applied to determine allele-specific primer extension products using Sequenom\'s MassARRAY system and iPLEX technology (Sequenom, San Diego, CA, USA). The design of oligonucleotides was carried out according to the guidelines of Sequenom and performed using MassARRAY Assay Design software (version 3.1). One study determined genotypes by direct sequencing. Genotyping was carried out for the remaining studies by nuclease assay (Taqman). Taqman genotyping reagents were designed by Applied Biosystems (Foster City, CA, USA) (<http://www.appliedbiosystems.com/>) as Assays-by-Design. Genotyping was performed using the ABI PRISM 7900HT, 7700 or 7500 Sequence Detection Systems according to the manufacturer\'s instructions. All studies complied with CIMBA genotyping quality control (QC) standards ([Antoniou *et al*, 2008](#bib3){ref-type="other"}).

Statistical analysis
--------------------

To test for departure from Hardy--Weinberg equilibrium, a single subject was randomly selected from each family and Pearson\'s *χ*^2^ Test (1 d.f.) was applied to genotypes from this sample set. The association of *ERCC4*-rs744154 with breast cancer risk was assessed by estimating hazard ratios (HR) and their corresponding 95% confidence intervals (CI) using weighted multivariable Cox proportional hazards regression with robust estimates of variance ([Antoniou *et al*, 2005](#bib2){ref-type="other"}). For each mutation carrier, we modelled the time to diagnosis of breast cancer from birth, censoring at the first of the following events: bilateral prophylactic mastectomy, breast cancer diagnosis, ovarian cancer diagnosis, death and last date known to be alive. Subjects were considered affected if they were censored at breast cancer diagnosis and unaffected otherwise. The weighted cohort approach involves assigning weights separately to affected and unaffected individuals such that the weighted observed incidences in the sample agree with established estimates for mutation carriers ([Antoniou *et al*, 2003](#bib1){ref-type="other"}). This approach has been shown to adjust for the bias in the HR estimates that is a consequence of the ascertainment criteria used ([Antoniou *et al*, 2005](#bib2){ref-type="other"}), which leads to an over-sampling of affected women. Weights were assigned separately for carriers of mutations in *BRCA1* and *BRCA2* and by age interval (\<25, 25--29, 30--34, 35--39, 40--44, 45--49, 50--54, 55--59, 60--64, 65--69, ⩾70).

We considered log-additive and codominant genetic models and tested these by applying in the first case a Wald test based on the log-HR estimate per allele and its standard error, and in the second the *χ*^2^ equivalent of a Wald test (on 2 degrees of freedom \[d.f.\]) based on the log-HR estimates for heterozygotes (CG) and minor-allele-homozygotes (GG) *vs* common homozygotes (CC) and the corresponding variance--covariance matrix. Additional independent variables included in all analyses were year of birth (\<1930, 1930--1939, 1940--1949, 1950--1959, 1960--1969, ⩾1970), study centre and country. Heterogeneity in HRs by study centre was assessed by the *χ*^2^ test described above, but applied to interaction terms for the per-allele effect by centre (on 33 d.f.). A number of sensitivity analyses were applied, including censoring at bilateral prophylactic oophorectomy (BPO), adjusting for BPO (as a time-varying covariate), excluding data used in the initial analysis (from CNIO, HEBCS and MBCSG) and excluding prevalent cases, defined as those diagnosed \>3 years before interview or DNA extraction. In addition, an alternative analysis based on a previously described retrospective likelihood approach ([Chenevix-Trench *et al*, 2007](#bib5){ref-type="other"}) was also applied using the pedigree analysis software MENDEL ([Lange *et al*, 1988](#bib13){ref-type="other"}).

All statistical analyses were carried out using Stata: Release 10 (StataCorp. 2007. Stata Statistical Software: Release 10.0. College Station, TX: Stata Corporation LP) unless otherwise stated. Robust estimates of variance were calculated using the *cluster* subcommand, applied to an identifier variable unique to each family.

Results and discussion
======================

It is thought that any SNP involved in the susceptibility to develop breast cancer in the general population could also be a phenotypic modifier in carriers of mutations in the high-risk susceptibility genes *BRCA1* and *BRCA2*. This has been confirmed in a recent report from CIMBA in which minor alleles in three SNPs in the *FGFR2*, *TNRC9* and *MAP3K1* genes, previously found to be associated with increased breast cancer risk in the general population ([Easton *et al*, 2007](#bib7){ref-type="other"}), were found to increase breast cancer risk in *BRCA1* and/or *BRCA2* mutation carriers as well ([Antoniou *et al*, 2008](#bib3){ref-type="other"}). We therefore aimed to investigate the role of the rs744154 SNP in *ERCC4* as a potential *BRCA1/BRCA2* risk modifier, based on our earlier finding that the minor G allele was associated with breast cancer protection in the general population (OR under a recessive model 0.61; *P*=0.0002) ([Milne *et al*, 2006](#bib16){ref-type="other"}).

This study was performed in two stages, the first analysing the SNP in 837 carriers of mutations (469 in *BRCA1* and 368 in *BRCA2*) from three CIMBA studies (CNIO, HEBCS and MBCSG). Results of the first stage are summarized in [Table 2](#tbl2){ref-type="table"}. We observed a marginally significant association of the G allele in *ERCC4*-rs744154 with breast cancer risk for both *BRCA1* (HR: 0.78, 95% CI: 0.60--1.00, *P*=0.05) and *BRCA2* (HR: 0.68, 95% CI: 0.45--1.02, *P*=0.06) mutation carriers. As this result was consistent with our previously reported protective association in the general population ([Milne *et al*, 2006](#bib16){ref-type="other"}), we genotyped this SNP in subjects from the remaining CIMBA studies and repeated the analysis in the combined series of 9408 *BRCA1* and 5632 *BRCA2* mutation carriers (see [Table 2](#tbl2){ref-type="table"}). However, when the whole CIMBA series was analysed (stage II), there was no longer evidence of an association with breast cancer risk for either *BRCA1* (HR: 0.98, 95% CI: 0.93--1.04, *P*=0.5) or *BRCA2* (HR: 0.97, 95% CI: 0.89--1.06, *P*=0.5) mutation carriers. Several sensitivity analyses were performed (see Materials and Methods) but results did not change substantially and so those from the main analysis are presented in this report.

Subsequent to the initiation of this study, a study from the Breast Cancer Association Consortium (BCAC), performed in \>30 000 breast cancer cases and 30 000 controls has now found no evidence for an association of rs744154 with breast cancer risk in the general population ([Gaudet *et al*, 2009](#bib10){ref-type="other"}). This is consistent with the lack of association found for *BRCA1* and *BRCA2* mutation carriers. These findings highlight the necessity of very large collaborative efforts to obtain reliable conclusions in genetic association studies. On the basis of the combined results obtained from the BCAC analysis of sporadic breast cancer and the CIMBA analysis of BRCA-related breast cancer -- each the largest study of its kind -- there no longer seems to be convincing evidence that *ERCC4*-rs744154 is associated with breast cancer risk.
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###### 

Number of *BRCA1* and *BRCA2* mutation carriers by study

  **Study**                                                                                           **Country of residence**   ***BRCA1***   ***BRCA2***   **Genotyping platform**
  --------------------------------------------------------------------------------------------------- -------------------------- ------------- ------------- -------------------------
  Breast Cancer Family Registry (BCFR)                                                                USA and Australia          492           356           Taqman
  Copenhagen Breast Cancer Study (CBCS)                                                               Denmark                    92            51            Taqman
  CNIO                                                                                                Spain and Greece^a^        149           198           Taqman
  Deutsches Krebsforschungszentrum (DKFZ)                                                             Germany                    68            27            Taqman
  Hereditary Breast and Ovarian study Netherlands (DNA-HEBON)                                         The Netherlands            768           293           iPlex^b^
  Epidemiological study of BRCA1 and BRCA2 mutation carriers (EMBRACE)                                UK and Eire                801           616           iPlex^b^
  Fox Chase Cancer Center (FCCC)                                                                      USA                        82            53            iPlex^b^
  German Consortium of Hereditary Breast and Ovarian Cancer (GC-HBOC)                                 Germany                    799           376           Taqman
  Genetic Modifiers of cancer risk in BRCA1/2 mutation carriers (GEMO)                                France                     1123          565           Taqman
  Gynecologic Oncology group (GOG)                                                                    USA                        391           275           Taqman
  Georgetown (GTN)                                                                                    USA                        29            17            iPlex^b^
  Hospital Clínico San Carlos (HCSC)                                                                  Spain                      109           94            Taqman
  Helsinki Breast Cancer Study (HEBCS)                                                                Finland                    102           104           iPlex^b^
  Iceland Landspitali -- University Hospital (ILUH)                                                   Iceland                                  86            Sequencing
  Interdisciplinary Health Research International Team Breast Cancer Susceptibility (INHERIT BRCAs)   Quebec-Canada              73            82            Taqman
  Kathleen Cuningham Consortium for Research into Familial Breast Cancer (kConFab)                    Australia                  488           388           iPlex^b^
  Mayo Clinic (MAYO)                                                                                  USA                        214           118           iPlex^b^
  Milan Breast Cancer Study Group (MBCSG)                                                             Italy                      344           218           Taqman
  Modifier Study of Quantitative Effects on Disease (ModSQuaD)                                        Czech Republic             271           128           Taqman
  Memorial Sloan-Kettering Cancer Center (MSKCC)                                                      USA                        255           157           Taqman
  Medical University of Vienna (MUV)                                                                  Austria                    281           120           iPlex^b^
  National Cancer Institute (NCI)                                                                     USA                        156           73            Taqman
  National Israeli Cancer Control Centre (NICCC)                                                      Israel                     309           196           Taqman
  N.N. Petrov Institute of Oncology (NNPIO)                                                           Russia                     66            0             Taqman
  Ontario Cancer Genetics Network (OCGN)                                                              Canada                     219           170           Taqman
  The Ohio State University Clinical Cancer Genetics Program (OSU CCG)                                USA                        60            31            Taqman
  Odense University Hospital (OUH)                                                                    Denmark                    217           131           Taqman
  Istituto Oncologico Veneto (IOVHBOCS)                                                               Italy                      93            88            Taqman
  Pisa Breast Cancer Study (PBCS)                                                                     Italy                      72            40            iPlex^b^
  Sheba Medical Centre (SMC)-Tel Hashomer                                                             Israel                     400           190           Taqman
  Swedish Breast Cancer Study (SWE-BRCA)                                                              Sweden                     411           120           iPlex^b^
  University of Turín Breast Cancer Study (UTBCS)                                                     Italy                      61            43            Taqman
  University of California Irvine (UCI)                                                               USA                        166           120           Taqman
  University of Pennsylvania (UPENN)                                                                  USA                        247           108           iPlex^b^
  Total                                                                                                                          9408          5632           

The CNIO series consisted of mutation carriers from the Spanish Consortium for the Study of Genetic Modifiers of *BRCA1* and *BRCA2* and the NCSR Demokritos, Athens, Greece.

Mutation carriers that failed genotyping are not included in the totals.

###### 

Genotype frequencies of *ERCC4*-rs744154 by mutation and disease status and hazard ratio estimates from stages I and II

                        **Genotype**   **Unaffected (%)**   **Affected (%)**   **HR^a^**   **95% CI**   ***P*-value**
  --------------------- -------------- -------------------- ------------------ ----------- ------------ ---------------
  *Stage I*^a^                                                                                          
   *BRCA1* (*n*=469)    CC             104 (50)             148 (57)           1.00                      
                        CG             85 (41)              96 (37)            0.86        0.62--1.20    
                        GG             19 (9)               17 (7)             0.49        0.24--1.01   0.1^b^
                        Per allele                                             0.78        0.60--1.00   0.05
                                                                                                         
   *BRCA2* (*n*=368)    CC             73 (45)              109 (53)           1.00                      
                        CG             81 (49)              82 (40)            0.66        0.40--1.09    
                        GG             10 (6)               13 (6)             0.50        0.17--1.47   0.2^b^
                        Per allele                                             0.68        0.45--1.02   0.06
                                                                                                         
  *Stage II*                                                                                            
   *BRCA1* (*n*=9408)   CC             2251 (51)            2603 (53)          1.00                      
                        CG             1836 (41)            1922 (39)          0.99        0.92--1.07    
                        GG             365 (8)              431 (9)            0.96        0.83--1.10   0.8^b^
                        Per allele                                             0.98        0.93--1.04   0.5
                                                                                                         
   *BRCA2* (*n*=5632)   CC             1288 (52)            1601 (51)          1.00                      
                        CG             1012 (40)            1300 (42)          1.05        0.93--1.18    
                        GG             200 (8)              231 (7)            0.82        0.65--1.02   0.09^b^
                        Per allele                                             0.97        0.89--1.06   0.5

837 mutation carriers from CNIO, MBCSG and HBCS were included in stage I. Additional mutation carriers from these centres were later genotyped and included in stage II, with carriers from other CIMBA centres. Total number of mutation carriers from these three centres included in the study is provided in [Table 1](#tbl1){ref-type="table"}.

2-d.f. test.
